StockData
Eikon Therapeutics, Inc. logo

Eikon Therapeutics, Inc. (EIKN) stock

EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.15−0.23 (-4.36%)

Close on Nov 17, 2026Market cap $278.95MP/E –Yield –

Eikon Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$75.46M–
Q1 FY2026Mar 31, 2026$70.05M–
Q2 FY2025Jun 30, 2025$69.19M–
Q1 FY2025Mar 31, 2025$56.59M–

More Eikon Therapeutics figures

See a number that looks wrong?